PERSPECTA

News from every angle

← Back to headlines

Martin Marietta and Alnylam Reaffirm 2026 Financial Guidance

Martin Marietta reaffirmed its 2026 adjusted EBITDA guidance, citing ahead-of-schedule integration, while Alnylam reiterated its 2026 TTR sales guidance and expanded clinical trial enrollment.

1 May, 02:23 — 1 May, 02:23
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed118d ago

Martin Marietta reaffirms 2026 adjusted EBITDA guidance of $2.43B midpoint as Quikrete integration runs ahead of plan

Read full article →

Related Stories

Trump Orders Immediate Renaming of Lake Ontario to Lake America

10m ago

Sudden Mountain Collapse Triggers Devastating Flash Flood in Nepal

14m ago

Fatal Road Accidents Reported Across the Balkans and Cyprus

30m ago

Reactions Pour In After Death of Convicted War Criminal Ratko Mladić

33m ago